US contract research organisation (CRO) PPD has set its sights on the Asian biopharma sector with new a lab at the heart of Singapore’s rapidly expanding drug development and trial industry.
Angel Biotechnology has inked a deal to manufacture the CTX stem cell line, which can now be frozen and thawed when needed, at its dedicated cell-based therapies plant that is equipped and licensed for the task.
Meridian Life Science (MLS) has completed the expansion of its cGMP biotech facility, which will enable the contract production of vaccines and viral based products for Phase I trials.
SAFC’s bioscience unit and Sartorius Stedim Biotech (SSB) have teamed up to create a suite of fluid management solutions that they hope will prove irresistible to the booming biomanufacturing sector.
Novasep has bolstered its upstream processing capabilities by acquiring Henogen, a Belgium-based CMO that has biotech development and cGMP manufacturing expertise.
Millipore has ramped up capacity for its Mobius range of single use bio-processing and manufacturing technologies with a new purpose built production facility in Danvers, Massachusetts.
CMO Kemwell is receiving technical assistance from Boehringer Ingelheim for the construction of its new biotech facility, which is designed to marry European technology with Indian low cost manufacturing.
French drug major Sanofi Aventis has unveiled plans for a €200m ($268m) biotechnology investment at its manufacturing facility in Vitry-sur-Seine near Paris, under its collaborative Biolaunch project.
SAFC and Vivalis have launched a new media designed to allow the latter’s commonly used virus producing EB66 cell line to grow at higher cell densities and produce higher yields.
ReceptoPharm, a subsidiary of US biotechnology company Nutra Pharma, is to start offering contract research and manufacturing services for life science companies.
Industrial manufacturing specialist Honeywell has been contracted to manage and control production processes at the newly constructed US operations of UK biotechnology company Shire.
Pall CEO Eric Krasnoff says delayed drug industry capital expenditure and moves to conserve inventory in the current global gloom caused life science sales to fall 8 per cent for the second quarter.
Drug raw materials maker Akron Biotechnology has selected Austin Chemical Company to help expand its client-base in the global biotech, pharmaceutical, and diagnostic industries.
Contract research group Recipharm has leased AstraZeneca Biotech Laboratory (ABL) in Sodertalje, Sweden, bolting on recombinant protein and monoclonal antibody development capabilities to its offering.
Disposable bioreactor specialist Wave Biotech AG of Switzerland has been snapped up by its commercial and development partner Sartorius-Stedim for an undisclosed sum.
Taiwan’s efforts to position itself as a major biotechnology hub received a further boost today with the opening of Merck KGaA’s dedicated technology training centre in Xizhi City, Taipei County.
Sartorius Stedim Biotech (SSB) and Bayer Technology Services (BTS) have signed an exclusive cooperation agreement for the manufacture and marketing of UVivatec products.
Indian pharmaceutical companies are making their first forays in the biotechnology arena, helping the market expand from a standing start at the beginning of the decade to reach a value of $2bn in 2006-7, according to a recent report from KPMG.
US CRO group Encorium has signed new contracts worth around $6.2m (€4.1m) under which it will conduct trials of a developmental vaccine on behalf of a global biopharmaceutical company.
People employed in the pharmaceutical industry in New Jersey, USA fell by one per cent in 2007, according to a report by the HealthCare Institute of New Jersey (HINJ).
in-PharmaTechnologist.com's round-up of developments in the pharmaceutical manufacturing space features news of TGA approval for Capsugel’s plant, Spain’s first therapeutic protein plant and Isogen setting up in Delaware.
Lonza is to co-develop and manufacture Novartis' biological pipeline as part of a long term strategic partnership that has been struck between the companies.
Vivalis has filed the biologics master file (BMF) with the US Food
and Drug Administration for its EB66 vaccine and therapeutic
protein production technology.
Outsourcing-Pharma.com presents its latest round-up of news in the
contract development and manufacturing sector, with updates from
Rentschler Biotechnologie, Eden Biodesign, Emcure Pharmaceuticals
and new start-up Appian Labs.
Europe is tipped to witness the most significant worldwide gains in
biopharmaceutical manufacturing production capacity in the coming
years, despite an overall global decline in capacity utilisation by
the industry.
Germany's Rentschler Biotechnologie and Boehringer Ingelheim have
inked a preferred partnership agreement to jointly offer customers
a more streamlined biopharmaceutical production option.
Malaysia's pharmaceutical star is likely to rise as of this year,
with an eventual position being gained amongst some of the world's
industry leaders being predicted by Frost & Sullivan.
Dutch biotech Crucell and its US partner DSM Biologics have
achieved a record yield of 15 grams per litre with their PER.C6
cell line technology for the production of monoclonal antibodies
and recombinant proteins.
A successful and strategically important year,' is how Sartorius
CEO Joachim Kreuzburg described 2007, a year highlighted
by merger of its biotechnology division with Stedim to boost its
presence in the burgeoning biopharmaceutical...
A new consortium in Scotland is to develop a new 3D cell assay for
use in drug discovery and for safety evaluation prior to clinical
trials, in the hope of cutting costs and reducing the use of
animals for testing.
Denmark's Novozymes has renewed and extended its collaboration with
UK-based biotech Upperton Limited on a drug delivery system that
exploits the natural binding properties of recombinant protein
nanoparticles to improve compound...
Lonza has revealed a profit hike for the full year of 2007,
reflecting the fruit of its "revised growth strategies"
across its business units, said the firm, which also announced its
"innovations" for future growth...
Processing specialist Sartorius Stedim Biotech today announced a
cooperation and supply deal with systems manufacturing firm Paul
Mueller Company for the US market, with a production facility in
Pennsylvania set to close as a result.
Millipore has announced the first fruit of its collaboration with
testing specialist Gen-Probe, with the launch of a new contaminant
detection system for biopharmaceutical manufacturers.
Separations expert Millipore is collaborating with Rohm and Haas
Company to develop new high-performance chromatography products for
use in biopharmaceutical manufacturing.
Tecan and GE Healthcare Life Sciences division are collaborating to
simplify high throughput (HT) protein purification by increasing
the speed and reliability of expression screening programmes.
Swiss pharma Novartis today announced the largest manufacturing investment in its history, revealing plans for a $700m (€486.5m) biotech facility to be built alongside its new solid dose plant in the low cost, high quality biopharma hub of Singapore.
Swiss supplier and services provider Lonza has added another
product to its catalogue of cell culture media, the most recent
addition to the offering of its new bioscience unit.
The burgeoning US contract assay services arena has witnessed the
arrival of a brand new player with the launch of ReachBio, which is
opening its business operations this week.
Vivalis is set to stamp out the Chinese Hamster Ovary (CHO) cell
line competition as the French company announces initial results in
a second study on monoclonal antibody production using its
avian-derived cell line.
French pharmaceutical firm LFB has announced its plans to
incrementally acquire fellow biotech company MAbgene through
the development of a new entity for a total of €6m.
Britain's Eden Biodesign has been selected by Cancer Research UK as
the beneficiary of two new biomanufacturing contracts as its
biomanufacturing business continues to grow.
Rentschler Biotechnologie has completed the first phase of a €50m
expansion of its biomanufacturing capacity with the launch of two
new bioreactors aimed at making protein-based drugs for biopharma
clients.
French firm Vivalis has announced the first data evaluating its
proprietary EBx cell lines for the production of monoclonal
antibodies (MAbs), with initial results suggesting high cytotoxic
properties in the resultant MAbs.
Danish firm Novozymes has been honoured by animal rights
organisation PETA for its efforts to provide animal-free
bioprocessing methods aimed at cutting animal testing during drug
development.